07:30 AM EDT, 06/23/2025 (MT Newswires) -- Merck ( MRK ) said Monday that Winrevair met the primary endpoint in the phase 3 trial in adults recently diagnosed with pulmonary arterial hypertension, showing statistically significant reduction in time to clinical worsening.

Winrevair significantly reduced the risk of clinical worsening events, including death, hospitalization and disease progression, according to the company.

Merck ( MRK ) said the trial was stopped early following positive interim analysis and a review of total clinical data.

Later this year, Merck ( MRK ) expects results to be presented at a medical meeting before submitting to regulatory authorities. Winrevair is currently approved in more than 45 countries.